TriSalus Life Sciences, Inc. Operating Income
TriSalus Life Sciences, Inc. (TLSI) reported Operating Income of -$9.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- TriSalus Life Sciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$9.81M.
- TriSalus Life Sciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$8.41M.
- TriSalus Life Sciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$3.27M.
- TriSalus Life Sciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$9.01M.
- TriSalus Life Sciences, Inc. operating income (loss) for fiscal 2025 was -$26.95M.
- TriSalus Life Sciences, Inc. operating income (loss) for fiscal 2024 was -$36.16M.
- TriSalus Life Sciences, Inc. operating income (loss) for fiscal 2023 was -$54.48M.
- TriSalus Life Sciences, Inc. operating income (loss) for fiscal 2022 was -$36.44M.
| Period end | Operating Income (Loss) 1 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 4 month | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.81M 10-Q · filed 2026-08-06 | -$18.22M 10-Q · filed 2026-08-06 | -$21.50M derived: sum of 3 quarters · filed 2026-08-06 | -$30.51M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2026-03-31 | -$8.41M 10-Q · filed 2026-05-12 | -$11.68M derived: sum of 2 quarters · filed 2026-05-12 | -$20.70M derived: sum of 3 quarters · filed 2026-05-12 | -$28.03M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2025-12-31 | -$3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$12.29M derived: sum of 2 quarters · filed 2026-03-05 | -$19.62M derived: sum of 3 quarters · filed 2026-08-06 | -$26.95M 10-K · filed 2026-03-05 | ||||||
| 2025-09-30 | -$9.01M 10-Q · filed 2025-11-13 | -$16.35M derived: sum of 2 quarters · filed 2026-08-06 | -$23.68M 10-Q · filed 2025-11-13 | -$31.25M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2025-06-30 | -$7.33M 10-Q · filed 2026-08-06 | -$14.66M 10-Q · filed 2026-08-06 | -$22.24M derived: sum of 3 quarters · filed 2026-08-06 | -$30.98M derived: sum of 4 quarters · filed 2026-08-06 | ||||||
| 2025-03-31 | -$7.33M 10-Q · filed 2026-05-12 | -$14.91M derived: sum of 2 quarters · filed 2026-05-12 | -$23.65M derived: sum of 3 quarters · filed 2026-05-12 | -$31.82M derived: sum of 4 quarters · filed 2026-05-12 | ||||||
| 2024-12-31 | -$7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$16.32M derived: sum of 2 quarters · filed 2026-03-05 | -$24.49M derived: sum of 3 quarters · filed 2026-03-05 | -$36.16M 10-K · filed 2026-03-05 | ||||||
| 2024-09-30 | -$8.74M 10-Q · filed 2025-11-13 | -$16.91M derived: sum of 2 quarters · filed 2025-11-13 | -$28.59M 10-Q · filed 2025-11-13 | -$42.83M derived: sum of 4 quarters · filed 2025-11-13 | ||||||
| 2024-06-30 | -$8.17M 10-Q · filed 2025-08-12 | -$19.85M 10-Q · filed 2025-08-12 | -$19.86M 10-Q · filed 2024-08-14 | -$34.09M derived: sum of 3 quarters · filed 2025-08-12 | -$52.71M derived: sum of 4 quarters · filed 2025-08-12 | |||||
| 2024-03-31 | -$11.67M 10-K/A · filed 2025-05-30 | -$11.69M 10-Q · filed 2024-05-15 | -$25.92M derived: sum of 2 quarters · filed 2025-05-30 | -$44.54M derived: sum of 3 quarters · filed 2025-05-30 | -$55.97M derived: sum of 4 quarters · filed 2025-05-30 | |||||
| 2023-12-31 | -$14.25M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-05-30 | -$32.86M derived: sum of 2 quarters · filed 2025-05-30 | -$44.30M derived: sum of 3 quarters · filed 2025-05-30 | -$54.48M 10-K/A · filed 2025-05-30 | -$54.15M 10-K · filed 2024-04-11 | |||||
| 2023-09-30 | -$18.62M 10-Q · filed 2024-11-14 | -$18.48M 10-Q · filed 2023-11-14 | -$30.05M derived: sum of 2 quarters · filed 2024-11-14 | -$40.23M 10-Q · filed 2024-11-14 | -$40.03M 10-Q · filed 2023-11-14 | -$51.94M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$11.43M 10-Q · filed 2024-08-14 | -$1.43M 10-Q · filed 2023-08-02 | -$21.55M 10-Q · filed 2024-08-14 | -$2.27M 10-Q · filed 2023-08-02 | -$33.33M derived: sum of 3 quarters · filed 2024-08-14 | -$41.44M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$10.12M 10-Q · filed 2024-05-15 | -$843.35K 10-Q · filed 2023-05-12 | -$21.89M derived: sum of 2 quarters · filed 2024-05-15 | -$30.00M derived: sum of 3 quarters · filed 2024-05-15 | -$30.29M derived: sum of 4 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | -$11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | -$19.88M derived: sum of 2 quarters · filed 2024-04-11 | -$20.17M derived: sum of 3 quarters · filed 2024-04-11 | -$36.44M 10-K · filed 2024-04-11 | -$2.75M 10-K · filed 2023-03-22 | |||||
| 2022-09-30 | -$8.11M 10-Q · filed 2023-11-14 | -$432.23K 10-Q · filed 2022-11-10 | -$8.40M derived: sum of 2 quarters · filed 2023-11-14 | -$24.67M 10-Q · filed 2023-11-14 | -$1.39M 10-Q · filed 2022-11-10 | -$10.21M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$288.27K 10-Q · filed 2023-08-02 | -$958.08K 10-Q · filed 2023-08-02 | -$2.10M derived: sum of 3 quarters · filed 2023-08-02 | -$2.91M derived: sum of 4 quarters · filed 2023-08-02 | ||||||
| 2022-03-31 | -$669.81K 10-Q · filed 2023-05-12 | -$1.81M derived: sum of 2 quarters · filed 2023-05-12 | -$2.62M derived: sum of 3 quarters · filed 2023-05-12 | -$3.40M derived: sum of 4 quarters · filed 2023-05-12 | ||||||
| 2021-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$1.95M derived: sum of 2 quarters · filed 2023-03-22 | -$2.73M derived: sum of 3 quarters · filed 2023-03-22 | -$3.04M 10-K · filed 2023-03-22 | ||||||
| 2021-09-30 | -$807.26K 10-Q · filed 2022-11-10 | -$1.59M derived: sum of 2 quarters · filed 2022-11-10 | -$1.90M 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | -$783.92K 10-Q · filed 2022-08-10 | -$1.09M 10-Q · filed 2022-08-10 | ||||||||
| 2021-03-31 | -$307.99K 10-Q · filed 2022-05-11 | |||||||||
| 2020-12-31 | -$108.49K 10-K · filed 2022-03-03 | |||||||||
| 2020-09-30 | -$1.00K 10-Q/A · filed 2021-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |